Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
FATE | US
0.01
0.31%
Healthcare
Biotechnology
30/06/2024
04/10/2024
3.22
3.23
3.35
3.16
Fate Therapeutics Inc. a clinical-stage biopharmaceutical company develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522 to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego California.
View LessLow Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
45.7%1 month
65.2%3 months
91.6%6 months
79.0%-
-
1.02
0.25
0.19
-2.59
16.42
-
-163.44M
366.69M
366.69M
-
-665.73
-
625.80
-42.10
12.51
15.16
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.85
Range1M
1.05
Range3M
2.90
Rel. volume
0.95
Price X volume
3.01M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Theravance Biopharma Inc | TBPH | Biotechnology | 8.1 | 396.27M | -1.34% | n/a | 24.09% |
Voyager Therapeutics Inc | VYGR | Biotechnology | 7.04 | 383.91M | 20.96% | 21.67 | 13.99% |
Biomea Fusion Inc. Common Stock | BMEA | Biotechnology | 10.48 | 379.48M | 3.46% | n/a | 9.95% |
ZVRA | ZVRA | Biotechnology | 7.2 | 378.85M | 1.12% | n/a | 183.10% |
C4 Therapeutics Inc | CCCC | Biotechnology | 5.38 | 373.04M | -0.92% | n/a | 27.69% |
Anika Therapeutics Inc | ANIK | Biotechnology | 24.99 | 369.77M | -0.12% | n/a | 13.35% |
ITOS | ITOS | Biotechnology | 10.02 | 365.95M | 2.04% | n/a | 0.83% |
Corvus Pharmaceuticals Inc | CRVS | Biotechnology | 5.64 | 352.79M | 6.82% | n/a | 1.37% |
INZY | INZY | Biotechnology | 5.17 | 346.90M | 2.78% | n/a | 49.47% |
Nautilus Biotechnology Inc. | NAUT | Biotechnology | 2.71 | 339.86M | -0.73% | n/a | 13.86% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.59 | 0.76 | Cheaper |
Ent. to Revenue | 16.42 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.02 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 91.62 | 74.67 | Riskier |
Debt to Equity | 0.25 | -1.82 | Expensive |
Debt to Assets | 0.19 | 0.26 | Cheaper |
Market Cap | 366.69M | 3.73B | Emerging |